Posted in Regulatory FDA points to liver injury with Amgen’s Tavneos April 1, 2026 Pharmaphorum The FDA has raised the pressure on Amgen to withdraw vasculitis drug Tavneos from the market with a report linking serious side effects to the drug. RegulatoryImmunology & InflammationRead full story